A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.
1 other identifier
observational
306
1 country
1
Brief Summary
In the single-centered, retrospective study, 306 hospital patients (including 129 diabetes and 177 non-diabetes patients) confirmed with SARS-CoV-2 infection were enrolled in Tongji Hospital, Wuhan, China. Clinical characteristics including clinical manifestation, laboratory parameters, lung CT features and clinical outcomes were compared between diabetes and non-diabetes patients. The prediction factors were analyzed for mortality of COVID-19 by univariate and multivariate analysis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 2, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 15, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2020
CompletedFirst Submitted
Initial submission to the registry
April 25, 2020
CompletedFirst Posted
Study publicly available on registry
April 28, 2020
CompletedApril 28, 2020
April 1, 2020
1 month
April 25, 2020
April 25, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Find the prediction factors associated with hospitalized death of patients with COVID-19 by univariate and multivariate analysis
28 days
Secondary Outcomes (3)
Demographics and clinical characteristics
28 days
Laboratory parameters and radiography image features
28 days
Treatment, complications and clinical outcomes
28 days
Study Arms (4)
Diabetes
Diabetes mellitus was diagnosed according to the standards of American Diabetes Association which were briefly described as FPG ≥ 7.0 mmol/L (Fasting is defined as no caloric intake for at least 8 h) or 2-h plasma glucose ≥ 11.1 mmol/L during Oral glucose tolerance test (OGTT), or with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose (RPG) ≥ 11.1 mmol/L. And in this group, we have 129 COVID-19 patients with diabetes.
Non-diabetes
Patients who do not meet the American Diabetes Association's standard diagnosis of diabetes are defined as non-diabetes. And in this group, we have 177 COVID-19 patients without diabetes.
Survivors
COVID-19 patients who survived on the 28th day in hospital belong to survivors group. In the survivors group, we included 201 patients with complete data.
Non-survivors
COVID-19 patients who did not survive on the 28th day in hospital belong to non-survivors group. In the non-survivors group, we included 54 patients with complete data.
Eligibility Criteria
The patients admitted from Feb 2, 2020 to Feb 15, 2020, diagnosed with SARS-CoV-2 pneumonia according to interim guidance of National health commission of the people's republic of China were enrolled. Laboratory confirmed cases were identified with positive viral RNA by real-time RT-PCR detection by the local health authority or our hospital from specimen taken from throat or nasal swab.
You may qualify if:
- Patients admitted from Feb 2, 2020 to Feb 15, 2020, diagnosed with SARS-CoV-2 pneumonia according to interim guidance of National health commission of the people's republic of China.
You may not qualify if:
- With SARS-CoV-2 RNA detection negative results.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tongji Hospitallead
Study Sites (1)
Tongji Hospital
Wuhan, Hubei, 430030, China
Related Publications (1)
Han M, Ma K, Wang X, Yan W, Wang H, You J, Wang Q, Chen H, Guo W, Chen T, Ning Q, Luo X. Immunological Characteristics in Type 2 Diabetes Mellitus Among COVID-19 Patients. Front Endocrinol (Lausanne). 2021 Mar 11;12:596518. doi: 10.3389/fendo.2021.596518. eCollection 2021.
PMID: 33776910DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Meifang Han, Professor
Tongji Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 25, 2020
First Posted
April 28, 2020
Study Start
February 2, 2020
Primary Completion
March 15, 2020
Study Completion
April 1, 2020
Last Updated
April 28, 2020
Record last verified: 2020-04
Data Sharing
- IPD Sharing
- Will not share